BioSpace News Archive

Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

Shareholders have been pleased with the company’s mRNA vaccine, but some, including the company’s cofounder, are cashing in on their stock gains.

The approval was specifically for patients with recurrent or advanced endometrial cancer who had progressed on or after previous treatment with platinum-based chemotherapy and whose cancers have a dMMR genetic anomaly.

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its clinical development activities. Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said : “ASLAN made significant progress in the fourth quart

DLH Holdings Corp., a leading healthcare and human services provider to the federal government, will release its financial results for the fiscal second quarter ended March 31, 2021 on May 5, 2021 after the market closes.

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report first quarter 2021 financial results on Wednesday, April 28, 2021 after the market close.

Nearly 19 million Americans who will decline vaccines would get vaccinated if they had a pill option, Vaxart’s poll finds

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report financial results for the first quarter ended March 31, 2021 after the market close on Wednesday, April 28, 2021.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced today that the first patient has been dosed in an investigator-initiated Phase 2 study to assess the efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB)-associated locally advanced/metastatic squamous cell carcinoma (SCC).

Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company’s financial results and business highlights for the first quarter ended March 31, 2021 as follows: